Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash from Financing Activities: 2023-2024

Historic Cash from Financing Activities for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $413.0 million.

  • Zenas BioPharma's Cash from Financing Activities fell 68.96% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.3 million, marking a year-over-year decrease of 81.44%. This contributed to the annual value of $413.0 million for FY2024, which is 1952.88% up from last year.
  • Per Zenas BioPharma's latest filing, its Cash from Financing Activities stood at $413.0 million for FY2024, which was up 1,952.88% from $20.1 million recorded in FY2023.
  • Over the past 5 years, Zenas BioPharma's Cash from Financing Activities peaked at $413.0 million during FY2024, and registered a low of $20.1 million during FY2023.
  • In the last 2 years, Zenas BioPharma's Cash from Financing Activities had a median value of $216.5 million in 2023 and averaged $216.5 million.
  • Data for Zenas BioPharma's Cash from Financing Activities shows a peak YoY surged of 1,952.88% (in 2024) over the last 5 years.
  • Zenas BioPharma's Cash from Financing Activities (Yearly) stood at $20.1 million in 2023, then skyrocketed by 1,952.88% to $413.0 million in 2024.